Why the study?
What is the dose-response relationship of pipecuronium bromide in elderly patients under balanced anesthesia?
What is the dose-response relationship of pipecuronium bromide in elderly patients under balanced anesthesia?
The cumulative dose-response of pipecuronium in elderly patients is consistent with younger populations, suggesting no dose adjustment is necessary.
May support unchanged pipecuronium dosing in elderly patients; leaves open confirmation in randomized trials.
Pipecuronium bromide is a new steroidal non-depolarizing muscle relaxant currently under investigation. It is similar to pancuronium with respect to the duration of action, but lacking its cardiovascular side effects. We examined the dose-response relation of pipecuronium in 27 patients, ages 66-79 years, utilizing the incremental dose method under balanced anesthesia. The ED50, ED90 and ED95 were 22.42 (5.2) mcg/kg, 31.81 (6.9) mcg/kg and 35.12 (7.8) mcg/kg, respectively (log probit method). Our recovery data also demonstrate that residual neuromuscular blockade due to pipecuronium can easily be antagonized with neostigmine as long as spontaneous recovery of T1- at the time of reversal administration is greater than 13%. The authors conclude that under balanced anesthesia the cumulative dose-response of pipecuronium in the elderly patients is consistent with those previously described for younger population. Therefore, no dose adjustment appears necessary for the elderly. However, as with all medications, careful administration is appropriate.
No takes yet. Share an insight, caveat, or question.
Azad et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: